Compound ID | 1307

Update compound information

CD201

Class: Lipopolysaccharide-binding immunotherapy agent

Spectrum of activity: Gram-negative
Details of activity: CD201 is active against panels of contemporary, clinically- relevant Gram-negative species (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii).
Institute where first reported: Cidara Therapeutics, Inc.
Year first mentioned: 2017
Highest developmental phase: Preclinical
Development status: Active
External links:
Citations:
  • http://ir.cidara.com/news-releases/news-release-details/t2-biosystems-and-cidara-therapeutics-announce-partnership
  • https://carb-x.org/wp-content/uploads/2019/05/2019.05.21-Portfolio-Pipeline-Formerly-Funded.pdf
  • https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Antibacterial+activity+of+CD201%2C+a+novel+lipopolysaccharide-binding+antibacterial+immunotherapy%2C+against+recent+Gram-negative+clinical+isolates%2C+including+colistin-+resistant+strains&id=2173&L=0&x=0&y=0

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.